瑞士生物制药公司救济治疗公司收到欧洲EB伤口治疗专利津贴通知,保护期至2040年;美国和中国的申请待决。 Swiss biopharmaceutical firm Relief Therapeutics receives Notice of Allowance for EB wound treatment patent in Europe, with protection until 2040; US and China applications pending.

瑞士生物制药公司Relief Therapeutics已收到欧洲专利局的许可通知, 申请其酸溶液专利, 包括用于治疗皮肤溶解 (EB) 伤口的研究药物RLF-TD011. Relief Therapeutics, a Swiss biopharmaceutical firm, has received a Notice of Allowance from the European Patent Office for a patent covering its hypochlorous acid solutions, including the investigational drug RLF-TD011, aimed at treating wounds from epidermolysis bullosa (EB). 该专利将保护欧洲的RLF-TD011,直到2040年,申请将在美国和中国进行。 The patent will protect RLF-TD011 in Europe until 2040, with applications pending in the U.S. and China. 该药物已得到林业发展局指定为孤儿的药物,具有潜在的市场独家经营权。 The drug has received orphan drug designation from the FDA, offering potential market exclusivity.